<DOC>
	<DOCNO>NCT00495924</DOCNO>
	<brief_summary>The purpose study determine whether early recurrence curative resection ductal pancreatic adenocarcinoma explain either dissemination cancer cell intraoperative tumour manipulation , post-operative systemic immune suppression , alteration biological property circulate cancer cell combination .</brief_summary>
	<brief_title>Perioperative Cancer Cell Dissemination Systemic Immune Suppression Resectable Ductal Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>Prognostic relevance circulate cancer cell immunosuppression resectable pancreatic carcinoma 1 . Introduction Pancreatic adenocarcinoma fourth commonest cause death cancer men woman , 5-year survival stage disease less 5 % . The case-fatality rate pancreatic cancer extremely high virtually identical number new case ( World Health Organization . World cancer report . Lyon : IACR Press ; 2003 ) . Most patient cancer pancreas diagnose advanced stage median survival 4 10 month , depend extent disease irrespective type treatment modality . Overall , few 5 % patient resection curative intent , though 80 % develop cancer recurrence ( Jemal A , Thomas A , Murray T , Thun M. Cancer Statistics . CA Cancer J Clin 2002 ; 52 : 23-47 ) . The primary site metastatic disease patient pancreatic cancer liver and/or peritoneal cavity . Cancer recurrence multifactorial determine patient- , tumour- , surgery-related factor . Any combination several mechanism propose cancer may recur follow potentially curative resection ( Coffey JC , Wang JH , Smith MJF , Bouchier-Hayes D , Cotter TG , Redmond HP . Excisional surgery cancer cure : therapy cost . Lancet Oncol 2003 ; 4:760-68 ) . Surgery may contribute overall residual tumor burden add disseminated cancer cell tumor manipulation . Due post-operative immunosuppression patient may become susceptible tumorigenesis and/or disseminate cancer cell may escape immune response easily . Finally , surgical resection may alter biological property cancer cell lead increase cellular proliferation reduce cell death . 2 . Cancer cell dissemination Solid marker lack predict cancer recurrence cancer progression measurable conventional modern diagnostic imaging . Molecular technique reverse transcriptase polymerase chain reaction ( RT-PCR ) technique proven highly sensitive method powerful tool study cancer metastasis ( Raj GV , Moreno JG , Gomella LG . Utilization Polymerase Chain Reaction Technology Detection Solid Tumors . Cancer 1998 ; 82 : 1419-42 ) . The prognostic relevance circulate cancer cell patient pancreatic cancer hardly study . In patient breast cancer number circulate cancer cell express EpCAM ( epithelial cell adhesion molecule ) proven independent predictor progression-free overall survival ( Cristofanilli M , Budd GT , Ellis MJ , Stopeck A , Matera J , Miller MC , Reuben JM , Doyle GV , Allard WJ , Terstappen LW , Hayes DF . Circulating tumor cell , disease progression , survival metastatic breast cancer . N Engl J Med 2004 ; 351 : 781-91 ) . EpCAM marker present epithelial cell tumour frequently overexpressed primary metastatic adenocarcinoma include pancreatic cancer ( Rao CG , Chianese D , Doyle GV , Miller MC , Russell T , Sanders RA Jr , Terstappen LW . Expression epithelial cell adhesion molecule carcinoma cell present blood primary metastatic tumor . Int J Oncol 2005 ; 27 : 49-57 ) . Also , marker CEA , CK20 , K-ras use detect disseminate pancreatic cancer cell . In patient colorectal carcinoma circulate cancer cell peripheral mesenteric venous blood detect RT-PCR , use CEA CK20 mRNA transcript , seem represent prognostic factor ( Yamaguchi K , Takagi Y , Aoki S , Futamura M , Saji S. Significant detection circulate cancer cell blood reverse transcriptase-polymerase chain reaction colorectal cancer resection . Ann Surg 2000 ; 232 : 58-65 . Guller U , Zajac P , Schnider A , Bösch B , Vorburger S , Zuber M , Spagnoli GC , Oertli D , Maurer R , Metzger U , Harder F , Heberer M , Marti WR . Disseminated single tumor cell detect real-time quantitative polymerase chain reaction represent prognostic factor patient undergoing surgery colorectal cancer . Ann Surg 2002 ; 236 : 768-76 ) . 3 . Molecular characteristic metastatic cancer cell The development metastasis highly selective process favor survival minor subpopulation metastatic cell . To produce metastasis , tumor cell subpopulation must complete sequence interrelated step . To produce clinically relevant distant metastasis , successful metastatic cell must therefore exhibit complex phenotype regulate transient permanent change gene level . Many malignant tumor , include pancreatic cancer , contain heterogeneous subpopulation cell . This heterogeneity exhibit wide range genetic , biochemical , immunological , biological characteristic growth rate , antigenic immunogenic status , cell surface receptor product , enzyme , karyotype , cell morphology , invasiveness , drug resistance , metastatic potential . It likely specific tumor cell colony within large heterogeneous tumor specimen forerunner distant metastasis . The overall efficiency whole metastatic process low . Although absolute number cancer cell require metastasis human unknown , positive relationship number circulate cancer cell subsequent development metastasis subject several experimental study ( Fisher , E.R . Fisher , B . Experimental study factor influence development hepatic metastasis circulate tumor cell . Acta Cytol . 9 : 146-159 , 1965 . Fidler , I.J . The relationship embolic homogeneity , number , size viability incidence experimental metastasis . Europ . J . Cancer 9 : 223-227 , 1973 . Liotta , L.A. , Kleinerman , J. , Saidel , G. Quantitative relationship intravascular tumor cell , tumor vessel pulmonary metastasis . Cancer Res . 34 : 977-1004 , 1974 . Weiss , L. , Mayhew , E. , Glaves , R.P . Holmes , J.C. Metastatic inefficiency mouse bear B16 melanoma . Br . J . Cancer 45 : 44-53 , 1982 . Topal B , Aerts JL , Roskams T , Fieuws S , Van Pelt J , Vandekerckhove P , Penninckx F. Cancer cell dissemination curative surgery colorectal liver metastasis . Eur J Surg Oncol 2005 ; 31 : 506-511 ) . The poor prognosis lack effective treatment pancreatic cancer arise several cause . There currently effective biomarkers useful early detection pancreatic cancer tend rapidly invade surround structure undergo early metastatic spreading . Moreover , pancreatic cancer highly resistant chemotherapy radiation therapy . Currently , molecular basis characteristic unknown . Gene expression profile provide important information molecular characteristic cancer use distinguish closely related cancer subtypes . Gene profile also use develop candidate biomarkers identify group gene involve specific functional aspect tumor biology . Gene expression profile could distinguish pancreatic tumor , chronic pancreatitis normal pancreatic tissue study extensively use different microarrays microarray platform . The differentially express gene pancreatic tumor tissue find quite specific highly reproducible among platforms study ( Crnogorac-Jurcevic T , Efthimiou E , Nielsen T , Loader J , Terris B , Stamp G , Baron A , Scarpa A Lemoine NR . Expression profile microdissected pancreatic adenocarcinoma . Oncogene 2002 ; 21 : 4587-4594 . Han H , Bearss DJ , Browne LW , Calaluce R , Naagle RB , Von Hoff DD . Identification differentially express gene pancreatic cancer cell use cDNA microarray . Cancer Res 2002 ; 62 : 2890-96 . Iacobuzio-Donahue CA , Ashfaq R , Maitra A , Adsay NV , Shen-Ong GL , Berg K , Hollingsworth MA , Cameron JL , Yeo CJ , Kern SE , Goggins M , Hruban RH . Cancer Res 2003 ; 63 : 8614-22 . Logsdon CD , Simeone DM , Binkley C , Arumugam T , Greenson JK , Giordano TJ , Misek DE , Hanash S. Molecular profile pancreatic adenocarcinoma chronic pancreatitis identifies multiple gene differentially regulate pancreatic cancer . Cancer Res 2003 ; 63 : 2649-57 ) . 4 . Peri-operative immunological change Suppression immune system feature post-operative stress response , natural killer ( NK ) lymphocyte activate killer ( LAK ) cell form integral component immune anti-tumor surveillance . However , tumor type-specific immune reaction pancreatic cancer patient undergo surgery lacking . Anti-tumoral activity NK LAK cell reduce immediately surgery additive effect surgery may sufficient improve ability disseminate cancer cell evade host immune response long enough metastasis develop ( Da Costa ML , Finnegan N , Flynn M , Bouchier-Hayes DJ . Laparotomy laparoscopy differentially accelerate experimental flank tumourgrowth . Br J Surg 1998 ; 85 : 1439-42 . ) ( Da Costa ML , Redmond HP , Bouchier-Hayes DJ . The effect laparotomy laparoscopy establishment spontaneous tumour metastasis . Surgery 1998 ; 124 : 516-26 ) . The suppressive immunological change follow surgical stress occur along temporal pattern . Depression cellular immunity tumor-associated antigen depression delayed-type hypersensitivity present 3 week surgery . In patient pancreatic cancer prevalence regulatory T cell ( Treg ) increase peripheral blood well tumour microenvironment . These Treg cell ( CD4+25+ ) phenotypically similar Treg cell normal donor coexpression CD45R0 CTLA-4 molecule well cytokine profile . Regulatory CD4+25+ lymphocytes infiltrate tumor regional lymph node , suppress activation CD8+ lymphocytes helper CD4+25- lymphocyte ( Liyanage , U. K. , T. T. Moore , H. G. Joo , Y. Tanaka , V. Herrmann , G. Doherty , J . A. Drebin , S. M. Strasberg , T. J. Eberlein , P. S. Goedegebuure , D. C. Linehan . 2002 . Prevalence regulatory T cell increase peripheral blood tumor microenvironment patient pancreas breast adenocarcinoma . J Immunol 169:2756 ) . However , oncological significance change activity number NK , LAK , Treg dendritic cell still confirm . 5 . Aims / Endpoints - Is number circulate cancer cell determinant cancer recurrence and/or survival follow potentially curative resection pancreatic cancer ? - Is genetic profile circulate cancer cell determinant cancer recurrence and/or survival follow potentially curative resection pancreatic cancer ? - Is peri-operative immunosuppression correlate cancer recurrence and/or survival follow potentially curative resection pancreatic cancer ? 6 . Patient selection inclusion criterion : Potentially curable/ resectable pancreatic cancer 7 . Study intervention - Quantitative analysis circulate cancer cell In present study peripheral venous blood sample obtain start surgery , end surgery , first day day 7 surgery central venous catheter . Tumour tissue sample random liver tru-cut biopsy obtain intra-operatively . Real-time quantitative RT-PCR technique ( TaqManR ) , base 3 different target marker ( CEA , CK20 EpCAM mRNA transcript ) beta-glucuronidase ( GUS ) control gene , use detect quantify circulate cancer cell blood stream . Normalized copy number ( NCN ) determine sample ( analyzed duplicate ) . RNA extraction sample perform use RNeasy mini kit ( Qiagen , BD Company ) . Sample preparation , cDNA synthesis PCR perform separate room order prevent cross-contamination . - Genetic profiling disseminate cancer cell Oligonucleotide microarray analysis mRNA extract primary pancreatic tumor disseminate cancer cell , day surgery . The focus study identify specific marker diagnosis drug target find indication metastasis study gene expression cancer cell circulate bloodstream . Our main objective analyze expression profile circulate pancreatic cancer cell . Changes analyze expression gene representative several different pathway frequently alter progression cancer tumor suppressor , oncogene , signal transduction molecule , growth factor angiogenesis factor . Gene expression profile data obtain apoptosis , cell cycle , cell growth differentiation , cell migration motility , signal transduction cancer-related gene . Latest development microarray technology comprise manufacture complete genome design new amplification strategy able analyze small sample less 1 ng total RNA ( Xiang CC , Chen M , Kozhich OA , Phan QN , Inman JM , Chen Y , Brownstein MJ . Probe generation directly small number cell DNA microarray study . Biotechniques 2003 ; 34 : 386-8 , 390 , 392-3 . Schindler H , Wiese A , Auer J , Burtscher H. cRNA target preparation microarrays : comparison gene expression profile generate different amplification procedure . Anal Biochem 2005 ; 344 : 92-101 . Puskás LG , Zvara Á , Hackler L Jr , Van Hummelen P. RNA amplification result reproducible microarray data slight ratio bias . Biotechniques 2002 ; 32 : 1330-1341 ) . In present study number cancer cell circulate blood stream expect extremely small . Therefore , linear RNA amplification ( T7 RNA-polymerase ) use order generate enough material label hybridization array . Two round amplification perform routinely . This perform successfully reproducibly start little 700 cell isolated via Laser Capture Microdissection ( data unpublished ) . - Preparation cell suspension microarrays isolate circulate cancer cell . Although microarray challenge know control , present study important specific challenge isolation enrichment circulate cancer cell . Currently , proportion circulate cancer cell nucleate blood cell ( leucocyte ) unknown patient suffer pancreatic cancer . Therefore , first step determine number cancer cell per ml blood pancreatic cancer patient determine variability among different patient . A second step develop enrichment method concentrate cancer cell without select specific type cancer cell loss information initial proportion cancer cell patient 's blood stream . The fast way isolate circulating cancer cell use flow cytometry density-gradient pre-enrichment combination negative selection strategy discard leukocyte ( CD45+ CD34+ ) sort 'circulating ' cancer cell . Isolating cell LCM use many time successfully microarray study . It report LCM easily dissect several thousand cell pancreatic tissue RNA-yield around 1ng/1000 cell ( Datson NA , Meijer L , Steenbergen PJ . Morsiak MC , van der Laan S , Meijer OC , de Kloet ER . Expression profile laser-microdissected hippocampal subregions rat brain reveals large subregion specific difference expression . Eur J Neurosci 2004 ; 20 : 2541-54 . Player A , Barrett JC , Kawasaki ES . Laser capture microdissection , microarrays precise definition cancer cell . Expert Rev Mol Diagn 2004 ; 4 : 831-40 . Espina V , Geho D , Mehta AI , Petricoin EF 3rd , Liotta LA , Rosenblatt KP . Pathology future : molecular profiling target therapy . Cancer Invest 2005 ; 23 : 36-46 . Crnogorac-Jurcevic T , Efthimiou E , Nielsen T , Loader J , Terris B , Stamp G , Baron A , Scarpa A Lemoine NR . Expression profile microdissected pancreatic adenocarcinoma . Oncogene 2002 ; 21 : 4587-4594 ) . - Immunological change Since tumor type-specific immune reaction pancreatic cancer patient undergo surgery lacking , present study assess systemic immunological change include cytokine level different time interval follow potentially curative surgery pancreatic cancer patient . PBMC extract peripheral venous blood use analysis FACS ( fluorescence-activated cell sorter ) determine prevalence : - CD3-19+ ( B-lymphocytes ) - CD3+56+ ( Killer cell ) - CD3-56+CD16+ ( NK natural killer cell ) - CD8+ ( Cytotoxic T-lymphocytes ) - CD4+25- ( Helper T-lymphocytes ) - CD4+25+127- ( Regulatory T-lymphocytes ) - Inflammatory cytokine peripheral blood ( IL-1b , IL-6 , IL-8 , IL-10 , IL-12 TNF ) analyse use commercially available 'BD Cytometric Bead Array ( CBA ) Human Inflammatory Kit ' . - PBMC ( peripheral blood mononuclear cell ) tumour tissue store liquid nitrogen analysis future study . 8 . Statistical analysis Univariate analysis well correct , multivariate analysis perform order identify optimally combine prognostic group factor : patient- , tumour- , treatment-associated factor well amount disseminate cancer cell , genetic expression profile immunological change follow surgery . The event study cancer recurrence ( disease free survival DFS ) death ( overall survival OS ) . 9 . Expected patient accrual `` Single center study '' : UZ.Gasthuisberg - KU.Leuven , Belgium Expected annual patient registration : 30 pt / year Duration patient accrual : 2 year</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Suspected ductal pancreatic adenocarcinoma ( pathological confirmation require resection tumour ) ; Informed consent . Any malignant tumour within 5 year prior pancreatic resection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>